Upon review of the study, Rachel Nazarian, MD, FAAD commented, “This study on Setria Glutathione suggests that when taken orally, Setria may decrease melanin production, lightening dark skin in individuals with Fitzpatrick skin types IV and V. When taken in doses of 250 mg per day, oral glutathione such as Setria is safe and well tolerated, with no evidence of any major adverse events. Given oral glutathione’s regulatory properties on melanogenesis and pigment production in the skin, this safe, reduced dosing may also help decrease the melanin index in individuals with darker skin tones. The study also reported that Setria may help wrinkle reduction in middle-aged women by improving water retention in sun-exposed areas of skin, aiding in hydration and possibly an improved skin barrier.”
“It was previously reported that oral GSH administration at 500 mg/day may help in brightening of skin color, and the main objective of this study was to find out whether Setria Glutathione maintains its skin brightening efficacy when given at a dose of 250mg/day,” said Yuki Nakamura, researcher at Kyowa’s Healthcare Product Development Center.
The randomized, double-blind, placebo-controlled study included healthy female-subjects aged 20-50 and provided Setria Glutathione (250 mg/day) or a placebo orally for 12 weeks. At each visit, at baseline and for 12 weeks, skin features including melanin index were measured. Blood samples were collected for safety monitoring. There were no serious adverse effects throughout the study.
A recent report from Global Industry Analysts, Inc (GIA) said the global market for skin lighteners is expected to reach $23 billion by 2020. Opportunities in the market are moving beyond women, with personal grooming gaining significance among men, particularly in Asia-Pacific markets.